NCT03543189 2026-01-29
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT00321698 2024-08-29
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT00214097 2019-11-25
Phase I/II Hypofractionated Radiotherapy for Prostate Cancer
University of Wisconsin, Madison
Phase 1/2 Completed
NCT00669162 2019-07-24
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT00769990 2017-12-13
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT00225420 2017-06-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00126165 2012-01-19
Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer
AHS Cancer Control Alberta
Phase 1/2 Completed